Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study

• Published in: Journal of cystic fibrosis 2022-03, Vol.21 (2), p.220-226
• Main Authors: Colombo, Carla, Alicandro, Gianfranco, Oliver, Mark, Lewindon, Peter J, Ramm, Grant A, Ooi, Chee Y., Alghisi, Federico, Kashirskaya, Nataliya, Kondratyeva, Elena, Corti, Fabiola, Padoan, Rita, Asherova, Irina, Evans, Helen, de Monestrol, Isabelle, Strandvik, Birgitta, Lindblad, Anders
• Format: Article
• Language: English
• Subjects: Cholagogues and Choleretics - adverse effects; Cohort Studies; Cohort study; Cystic fibrosis; Cystic Fibrosis - complications; Humans; Hypertension, Portal - drug therapy; Hypertension, Portal - epidemiology; Medicin och hälsovetenskap; Portal hypertension; Retrospective Studies; Ursodeoxycholic acid; Ursodeoxycholic Acid - adverse effects; Young Adult
• ISSN: 1569-1993; 1873-5010; 1873-5010
• DOI: 10.1016/j.jcf.2021.03.014

•Incidence of liver outcome evaluated in UDCA prescribing vs. non-prescribing centers.•No significant difference in cumulative incidence of portal hypertension was identified.•No significant differences in liver-related and other-cause mortality were found. The efficacy and safety of ursodeoxycholic acid (UDCA) for the treatment of liver disease associated with cystic fibrosis (CF) are under discussion, and clinical practice varies among centers. The study aimed at evaluating if the incidence of severe liver disease differs between CF centers routinely prescribing or not prescribing UDCA. We carried out a retrospective multicenter cohort study including 1591 CF patients (1192 patients from UDCA-prescribing centers and 399 from non-prescribing centers) born between 1990 and 2007 and followed from birth up to 31 December 2016. We computed the crude cumulative incidence (CCI) of portal hypertension (PH) at the age of 20 years in the two groups and estimated the subdistribution hazard ratio (HR) through a Fine and Gray model. Over the observation period, 114 patients developed PH: 90 (7.6%) patients followed-up in UDCA prescribing centers and 24 (6.0%) in non-prescribing centers. The CCI of PH at 20 years was 10.1% (95% CI: 7.9-12.3) in UDCA-prescribing and 7.7% (95% CI: 4.6-10.7) in non-prescribing centers. The HR among patients followed in prescribing centers indicated no significant difference in the rate of PH either in the unadjusted model (HR: 1.21, 95% CI: 0.69-2.11) or in the model adjusted for pancreatic insufficiency (HR: 1.28, 95% CI: 0.77-2.12). CF patients followed-up in UDCA prescribing centers did not show a lower incidence of PH as compared to those followed in centers not prescribing UDCA. These results question the utility of UDCA in reducing the occurrence of severe liver disease in CF.